- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05001737
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE (EMERALD)
A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study NI-0501-14 is a two-cohort trial that enrolls subjects who are diagnosed with sHLH/MAS (MAS being a form of secondary HLH) and who are presenting an inadequate response to high doses of GCs. These subjects will be enrolled in 2 cohorts as per their background disease. The cohorts are defined as follows:
- Cohort 1: MAS in the context of sJIA and AOSD.
- Cohort 2: MAS in the context of pediatric and adult SLE.
The study has the objectives to investigate the efficacy, safety and tolerability, for 8 weeks, and PK and PD, QoL and immunogenicity in these 2 cohorts for up to 1 year after last dose of of emapalumab.
Macrophage Activation Syndrome (MAS) Secondary Hemophagocytic Lymphohistiocytosis (sHLH) systemic Juvenile Idiopathic Arthritis (sJIA) Adult-onset Still's Disease (AOSD) Systemic Lupus Erythematosus (SLE)
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Anna Westerdahl
- Email: Anna.Westerdahl@sobi.com
Study Contact Backup
- Name: Adnan Mahmood, MD
- Phone Number: +46(0)8 697 20 00
- Email: Adnan.Mahmood@sobi.com
Study Locations
-
-
-
Leuven, Belgium
- Recruiting
- Universitair Ziekenhuis Leuven
-
Contact:
- Dr. De Somer, MD
-
-
-
-
-
Calgary, Canada
- Recruiting
- Alberta Children's Hospital
-
Contact:
- Dr. Benseler, MD
-
Calgary, Canada
- Recruiting
- University of Calgary
-
Contact:
- Dr. MacMullan, MD
-
Montréal, Canada
- Recruiting
- Centre Hospitalier de l'Université de Montréal
-
Contact:
- Dr. Chapdelaine, MD
-
Montréal, Canada
- Recruiting
- Centre Hospitalier Universitaire Sainte-Justine
-
Contact:
- Dr. Decaluwe, MD
-
Toronto, Canada
- Recruiting
- Hospital For Sick Children
-
Contact:
- Dr. Levy, MD
-
-
-
-
-
Beijing, China
- Recruiting
- Beijing Friendship Hospital
-
Contact:
- Dr. Wang, MD
-
Beijing, China
- Recruiting
- Beijing Children's Hospital
-
Contact:
- Dr. Li, MD
-
Shanghai, China
- Recruiting
- Children's Hospital of Fudan University
-
Contact:
- Dr. Sun, MD
-
-
-
-
-
Olomouc, Czechia
- Recruiting
- Fakultní nemocnice Olomouc
-
Contact:
- Dr. Bouchalova, MD
-
Praha, Czechia
- Recruiting
- Vseobecna fakultni nemocnice v Praze
-
Contact:
- Dr. Dolezalova, MD
-
-
-
-
-
Lille, France
- Recruiting
- Hopital Claude Huriez
-
Contact:
- Dr. Hachulla, MD
-
Contact:
- Dr. Terriou, MD
-
Marseille, France
- Recruiting
- Hôpital de la Conception
-
Contact:
- Dr. Kaplanski, MD
-
Paris, France
- Recruiting
- Hopital Universitaire Pitie Salpetriere
-
Contact:
- Dr. Fautrel, MD
-
Paris, France
- Recruiting
- Hôpital Necker-Enfants Malades
-
Contact:
- Dr. Quartier, MD
-
-
-
-
-
Berlin, Germany
- Recruiting
- Charité Universitätsmedizin
-
Contact:
- Dr. Biesen, MD
-
Heidelberg, Germany
- Recruiting
- Universitätsklinikum Heidelberg
-
Contact:
- Dr. Blank, MD
-
-
-
-
-
Genova, Italy
- Recruiting
- IRCCS G. Gaslini
-
Contact:
- Dr. Gattorno, MD
-
Milano, Italy
- Recruiting
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Contact:
- Dr. Filocamo, MD
-
Roma, Italy
- Recruiting
- Ospedale Pediatrico Bambino Gesu
-
Contact:
- Dr. De Benedetti, MD
-
Trieste, Italy
- Recruiting
- IRCCS - Materno-Infantile Burlo Garofolo
-
Contact:
- Dr. Tommasini, MD
-
-
-
-
-
Kawasaki, Japan
- Recruiting
- St. Marianna University School of Medicine Hospital
-
Contact:
- Dr. Mori, MD
-
Takatsuki, Japan
- Recruiting
- Osaka Medical and Pharmaceutical University Hospital
-
Contact:
- Dr. Ozeki, MD
-
Tokyo, Japan
- Recruiting
- Tokyo Medical and Dental University Hospital
-
Contact:
- Dr. Shimizu, MD
-
Yokohama, Japan
- Recruiting
- Yokohama City University Hospital
-
Contact:
- Dr. Ito, MD
-
-
-
-
-
Utrecht, Netherlands
- Recruiting
- UMC Utrecht
-
Contact:
- Dr. Vastert, MD
-
-
-
-
-
Kraków, Poland
- Recruiting
- Szpital Specjalistyczny im. J. Dietla w Krakowie
-
Contact:
- Pr. Dr. Batko, MD
-
Kraków, Poland
- Recruiting
- Wojewódzki Specjalistyczny Szpital Dzieciecy im. Sw. Ludwika w Krakowie
-
Contact:
- Dr Zuber, MD
-
Poznań, Poland
- Recruiting
- Ortopedyczno - Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
-
Contact:
- Dr. Samborski, MD
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Hospital Sant Joan de Déu
-
Contact:
- Dr. Antón López, MD
-
La Paz, Spain
- Recruiting
- Hospital Universitario
-
Contact:
- Dr. Robles-Marhuenda, MD
-
La Paz, Spain
- Terminated
- Hospital Universitario La Paz
-
Valencia, Spain
- Recruiting
- Hospital Universitari i Politecnic La Fe
-
Contact:
- Dr. Calvo Penade, MD
-
-
-
-
-
Stockholm, Sweden
- Recruiting
- Karolinska Universitetssjukhuset Solna
-
Contact:
- Dr. Faustini, MD
-
Stockholm, Sweden
- Recruiting
- Karolinska Universitetssjukhuset Solna (Ped. Rheum.)
-
Contact:
- Dr. Horne, MD
-
-
-
-
-
London, United Kingdom
- Recruiting
- Great Ormond Street Hospital
-
Contact:
- Dr. Brogan, MD
-
London, United Kingdom
- Recruiting
- Imperial College Healthcare NHS Trust
-
Contact:
- Dr. Youngstein, MD
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- UAB Hospital
-
Contact:
- Dr. Rubio, MD
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA Health
-
Contact:
- Dr. McCurdy, MD
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida
-
Contact:
- Dr. Elder, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Recruiting
- Children's Healthcare of Atlanta
-
Contact:
- Dr. Chandrakasan, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Withdrawn
- Boston Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota Masonic Children's Hospital
-
Contact:
- Dr. Binstadt, MD
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Recruiting
- Akron Children's Hospital
-
Contact:
- Dr. Cook, MD
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Dr. Grom, MD
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital, Abigail Wexner Research Institute
-
Contact:
- Dr. Akoghlanian, MD
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- UPMC Children's Hospital of Pittsburgh
-
Contact:
- Dr. Rosenkranz, MD
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Recruiting
- Primary Children's Hospital
-
Contact:
- Dr. Hersh, MD
-
-
Washington
-
Seattle, Washington, United States, 98195
- Recruiting
- Rheumatology Clinic at University of Washington Medical Center - Roosevelt
-
Contact:
- Dr Singh, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria Run-in phase in all cohorts
- Informed consent provided by the subject or by the subject s' legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as required by local law.
- Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of MAS.
- MAS defined as per the criteria defined below for each cohort and requiring treatment with GCs.
Interventional phase in all cohorts
- Informed consent provided by the subject or by the subject's legally authorized representative(s) with the assent of subjects who are legally capable of providing it, as as required by local law.
- Male and female subjects aged between 6 months and 80 years of age at the time of diagnosis of active MAS.
- Subjects who have shown an inadequate response to high dose intravenous (i.v.) GCs administered for at least 3 days according to local standard clinical practice, including but not limited to pulses of 30 mg/kg PDN on 3 consecutive days. High i.v. GCs dose is recommended not to be lower than 2 mg/kg/ day PDN equivalent (or at least 60 mg/day in pediatric subjects of 30 kg or more, and at least 1g/day in adult MAS subjects). In case of rapid worsening of the subject's condition and/or laboratory parameters, as per Investigator judgment, inclusion may occur within less than 3 days from starting high dose GCs.
Diagnosis of active MAS confirmed by the treating rheumatologist, having ascertained the followings:
a. Febrile subjects presenting with ferritin > 684 ng/mL. b. and any 2 of: i. Platelet count ≤ 181 x109/L ii. AST-level > 48 U/L iii. Triglycerides > 156 mg/dL iv. Fibrinogen level ≤ 360 mg/dL
Female subjects of child-bearing potential willing to use highly effective methods of contraception from study drug initiation to 6 months after the last dose of study drug.
Specific inclusion criteria to Cohort 1 and Cohort 2
Cohort 1:
- Confirmed sJIA diagnosis. For subjects presenting with MAS in the context of the onset of sJIA, high presumption of sJIA will suffice for eligibility.
- Confirmed diagnosis of AOSD as per Yamaguchi criteria.
Cohort 2:
- Confirmed diagnosis of SLE as per SLICC'12 criteria.
Exclusion criteria
- Primary HLH documented by either the presence of a known causative genetic mutation or abnormal perforin expression and CD107a degranulation assay as described with primary hemophagocytic lymphohistiocytosis or by the presence of family history.
- Confirmed malignancy. Note: subjects with a suspected malignancy should have mononuclear cells typed by flow cytometry and/or tissue biopsy, as applicable, to rule out malignancy.
- Treatment with canakinumab, JAK inhibitors, TNF inhibitors and tocilizumab at the time of emapalumab initiation.
- Ongoing treatment with anakinra at a dose above 4 mg/kg at time of emapalumab initiation.
- Subjects treated with etoposide for MAS in the last 1 month.
- Clinically active mycobacteria (typical and atypical), Histoplasma Capsulatum, or Salmonella infections.
- Evidence of leishmania infections.
- Evidence of latent tuberculosis.
- History of hypersensitivity or allergy to any component of the study drug.
- Receipt of a Bacillus Calmette-Guerin (BCG) vaccine within 12 weeks prior to screening.
- Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screening.
- Pregnancy or lactating female subjects.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 (sJIA and AOSD) and Cohort 2 (SLE)
MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE
|
Emapalumab iv infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with complete response (CR) at Week 8 after first administration of emapalumab
Time Frame: 8 weeks
|
Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm. Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm. Clinical signs will be considered as resolved if VAS is below or equal to 1/10. And Normalization of laboratory parameters relevant to MAS, as follows: WBC above LLN platelet count above LLN LDH below 1.5 ULN ALT below 1.5 ULN AST below 1.5 ULN fibrinogen higher than 100 mg/dL ferritin levels decreased by at least 80 % from values at screening or baseline (whichever is higher) or below 2000 ng/ml, whichever is low |
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GCs tapering to a dose below 50% of prednisolone (PDN) equivalent at the time of emapalumab start or to the same (or lower) dose being administered before the occurrence of MAS whichever occurs first
Time Frame: At any time in the study, up to 1 year
|
GC tapering as per investigator discretion
|
At any time in the study, up to 1 year
|
GCs tapering to ≤1mg/kg/day of PDN equivalent at any time during the study.
Time Frame: At any time in the study, up to 1 year
|
GC tapering as per investigator discretion
|
At any time in the study, up to 1 year
|
Time to achieve GCs tapering as defined above.
Time Frame: At any time in the study, up to 1 year
|
GC tapering as per investigator discretion
|
At any time in the study, up to 1 year
|
Time to first Complete Remission
Time Frame: At any time in the study, up to 1 year
|
Time to CR
|
At any time in the study, up to 1 year
|
Proportion of subjects with overall response as defined by CR or PR
Time Frame: At any time in the study, up to 1 year
|
Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm.
|
At any time in the study, up to 1 year
|
Time to first overall response as defined by CR or PR
Time Frame: At any time in the study, up to 1 year
|
CR defined as below: Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm. |
At any time in the study, up to 1 year
|
MAS recurrence at anytime after achievement of CR
Time Frame: At any time after CR, up to 1 year
|
Time to MAS recurrence after CR
|
At any time after CR, up to 1 year
|
Withdrawal from the study due to lack of response as per Investigator decision
Time Frame: At any time in the study, up to 1 year
|
Time to withdrawal
|
At any time in the study, up to 1 year
|
Survival time
Time Frame: At any time in the study, up to 1 year
|
Time to Survival
|
At any time in the study, up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs) (serious and non-serious).
Time Frame: At any time in the study, up to 1 year
|
Incidence, severity, causality and outcomes of AEs
|
At any time in the study, up to 1 year
|
Study interruption due to safety reasons
Time Frame: At any time in the study, up to 1 year
|
Number of subjects withdrawn due to safety reasons
|
At any time in the study, up to 1 year
|
Laboratory parameters
Time Frame: At any time in the study, up to 1 year
|
Changes from baseline
|
At any time in the study, up to 1 year
|
Patient reported outcomes : PedsQL™;
Time Frame: Screening, Week 8, month 6 and 1 year
|
Pediatric Quality of Life Inventory (PedsQL™; Generic Core Scales and Infant Scales, Acute versions)
|
Screening, Week 8, month 6 and 1 year
|
Patient reported outcomes: Patient/Parent Global Impression of Severity
Time Frame: Screening, Week 8, month 6 and 1 year
|
Health-related quality of life: Global Assessment: Patient/Parent Global Impression of Severity
|
Screening, Week 8, month 6 and 1 year
|
Patient reported outcomes: Clinician Global Impression of Severity
Time Frame: Screening, Week 8, month 6 and 1 year
|
Health-related quality of life: Global Assessment: Clinician Global Impression of Severity
|
Screening, Week 8, month 6 and 1 year
|
PK endpoints
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
Serum concentrations of emapalumab vs. time
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK endpoints CEOI,
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK parameters by non-compartmental analysis: CEOI,
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK endpoints: λz,
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK parameters by non-compartmental analysis: λz,
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK endpoints: CL,
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK parameters by non-compartmental analysis: CL,
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK endpoints: Vss,
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK parameters by non-compartmental analysis: Vss,
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK endpoints: MRTlast and MRTinf
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PK parameters by non-compartmental analysis: MRTlast and MRTinf, as applicable
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PD endpoints per cohort: free IFN-γ and total IFNγ
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
• Levels of circulating free IFN-γ at pre-dose, and total IFNγ (free IFN-γ+bound to emapalumab) after initiation of the study drug.
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PD endpoints per cohort: chemokines
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
Levels of the main IFN-γ-induced chemokines (CXCL9, CXCL10).
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
PD endpoints per cohort: sCD25)
Time Frame: Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
Levels of MAS markers (sCD25).
|
Every treatment visit until week 8, Day 60, Day 100, 6 months, 1 year
|
Immunogenicity endpoints
Time Frame: Treatment visit 1, week 8, 6 months, 1 year
|
Occurrence of ADAs, Nab to emapalumab
|
Treatment visit 1, week 8, 6 months, 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Brian Jamieson, MD, Swedish Orphan Biovitrum
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NI-0501-14
- 2021-001577-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
AstraZenecaRecruitingActive Systemic Lupus ErythematosusChina, Korea, Republic of, Philippines, Taiwan, Thailand, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
I-Mab Biopharma Co. Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Changhai HospitalRui Therapeutics Co., LtdRecruitingSystemic Lupus Erythematosus (SLE)China
Clinical Trials on Emapalumab
-
M.D. Anderson Cancer CenterSobi, Inc.Not yet recruiting
-
Swedish Orphan BiovitrumCompletedStudy to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic LymphohistiocytosisPrimary Hemophagocytic LymphohistiocytosisSpain, United States, United Kingdom, Germany, Italy, Sweden, Canada, Switzerland
-
Swedish Orphan BiovitrumActive, not recruitingPrimary Hemophagocytic LymphohistiocytosisChina
-
Swedish Orphan BiovitrumCompletedArthritis, Juvenile | Lymphohistiocytosis, Hemophagocytic | Macrophage Activation Syndrome | Adult Onset Still DiseaseUnited States, Spain, United Kingdom, France, Italy
-
Swedish Orphan BiovitrumSeventh Framework ProgrammeCompletedHemophagocytic LymphohistiocytosisUnited States, France, Italy, Spain, United Kingdom
-
Swedish Orphan BiovitrumLight Chain Bioscience - Novimmune SATerminatedHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumPRA Health Sciences; Cromsource; BioMérieux; Q2 Solutions; Cytel Inc.; ABF Pharmaceutical...Terminated
-
Instituto Bioclon S.A. de C.V.University of ArizonaCompletedBlood Coagulation Disorders | Snake BiteUnited States
-
Swedish Orphan BiovitrumTerminated
-
Memorial Sloan Kettering Cancer CenterSobi, Inc.RecruitingImmune System Diseases | Autoimmune Lymphoproliferative | Primary Immune Regulatory DisorderUnited States